Skip to main content
SpringerLink
Log in

Short- and long-term changes of quality of life in patients with acromegaly: Results from a prospective study

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Quality of life (QoL) may be affected in acromegalic patients, although the role of disease activity is still unsettled. The aim of the study was to assess the QoL of acromegalic patients with a specific questionnaire (ACROQOL). ACROQOL was evaluated in a prospective study (at baseline, at 6 and 24 months) in 23 active untreated acromegalic patients. Control of acromegaly was defined by normal age-matched serum IGF-I concentrations. Patient groups were defined as controlled or uncontrolled at 6 months and at 24 months: controlled or uncontrolled during the entire study period (ACROCC or ACRONC, respectively) or uncontrolled at 6 months and controlled thereafter (ACROC). At 6 months, ACROQOL scores improved globally (from 54.3±21 to 65.1±19, p=0.04) as did subdomains and were inversely related to IGF-I variation (r=−0.50, p=0.052). At 24 months, ACROQOL improved globally (from 54.3±21 to 65.7±18.0, p=0.04) and this was also seen in the appearance subdomains; however, no correlation was revealed between variation of serum IGF-I concentrations and changes in ACROQOL total score (r=0.008, p=0.87). ACROQOL scores did not significantly change in ACRONC (p=0.310) and in ACROC (p=0.583), whereas it improved globally (from 42.1±22.1 to 58.8±16.04, p=0.021) and in psychological subdomains in ACROCC; however, it reflected the improvement occurred within the first 6 months of disease control. In conclusion, successful treatment, which normalizes disease activity, improves QoL in acromegaly in the short term. However, the lack of correlation between the ACROQOL score in the long term might suggest that factors other than serum IGF-I participate in the well-being of acromegalic patients; however, due to the small sample size, our results need to be confirmed in larger studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558–73.

    Article  CAS  PubMed  Google Scholar 

  2. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA, Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008, 93: 61–7.

    Article  CAS  PubMed  Google Scholar 

  3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25: 102–52.

    Article  CAS  PubMed  Google Scholar 

  4. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730–4.

    CAS  PubMed  Google Scholar 

  5. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002, 57: 251–8.

    Article  CAS  Google Scholar 

  6. Bates AS, Van’t Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293–9.

    CAS  PubMed  Google Scholar 

  7. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol and Metab 2004, 89: 5369–76.

    Article  CAS  Google Scholar 

  8. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005, 90: 2731–9.

    Article  CAS  PubMed  Google Scholar 

  9. Kauppinen-Makelin R, Sane T, Sintonen H et al. Finnish Acromegaly Study Group. Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 2006, 91: 3891–6.

    Article  CAS  PubMed  Google Scholar 

  10. Rowles S, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severly impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 2005, 90: 3337–41.

    Article  CAS  PubMed  Google Scholar 

  11. Paisley AN, Rowles SV, Roberts ME, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 2007, 67: 358–62.

    Article  CAS  Google Scholar 

  12. Colao A, Martino E, Cappabianca P et al. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006, 29: 1017–20.

    Article  CAS  PubMed  Google Scholar 

  13. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: An evolving concept? J Endocrinol Invest 2006, 29: 86–93.

    Article  CAS  PubMed  Google Scholar 

  14. Colao A, Arnaldi G, Beck-Peccoz P, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 2007, 30: 693–9.

    Article  CAS  PubMed  Google Scholar 

  15. Giustina A, Mancini T, Boscani PF, et al. Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. J Endocrinol Invest 2008, 31: 731–8.

    Article  CAS  PubMed  Google Scholar 

  16. Glantz SA. Primer of Biostatistics. New York: McGraw-Hill, 2002.

  17. StatXact 4, version 4.0.1. Cytel Software Corporation, Cambridge, MA, USA.

  18. Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M. Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom 1999, 68: 165–7.

    Article  CAS  PubMed  Google Scholar 

  19. Gilbert J, Ketchen M, Kane P et al. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 2003, 6: 11–8.

    Article  CAS  PubMed  Google Scholar 

  20. Webb SM, Badia X, Surinach N; Spanish AcroQol Study Group. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQol: a 6-month prospective study. Eur J Endocrinol 2006, 155: 269–77.

    Article  CAS  PubMed  Google Scholar 

  21. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 2006, 155: 831–7.

    Article  CAS  PubMed  Google Scholar 

  22. Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 2006, 27: 287–317.

    Article  CAS  PubMed  Google Scholar 

  23. Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration and functional plasticity in the adult brain. ScientificWorld-Journal 2006, 6: 53–80.

    Article  PubMed  CAS  Google Scholar 

  24. Matta M, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of ppatients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 2008, 158: 305–10.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, University of Pisa, Ospedale Cisanello, Via Paradisa 2, 56124, Pisa, Italy

    C. Sardella, M. Lombardi, C. Cosci, S. Brogioni, I. Scattina, E. Martino & F. Bogazzi MD

  2. Unit of Epidemiology and Biostatistics, Institute of Clinical Physiology, National Research Council (C.N.R.), Pisa, Italy

    G. Rossi

  3. Department of Endocrinology, Autonomous University of Barcelona, Barcelona, Spain

    S. M. Webb

  4. University of Molise, Campobasso, Italy

    M. Gasperi (Chair of Endocrinology)

Authors
  1. C. Sardella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Lombardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. G. Rossi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C. Cosci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Brogioni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. I. Scattina
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. M. Webb
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M. Gasperi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E. Martino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. F. Bogazzi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Bogazzi MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sardella, C., Lombardi, M., Rossi, G. et al. Short- and long-term changes of quality of life in patients with acromegaly: Results from a prospective study. J Endocrinol Invest 33, 20–25 (2010). https://doi.org/10.1007/BF03346555

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346555

Key-words

Search

Navigation